Three histories, different missing pieces

These three molecules correspond to two products in the care route described here. Promise Peptides offers Semax and Selank together as one blend, alongside a distinct DSIP product. The blend explanation addresses why evidence on an ingredient cannot establish the effects of that combination.

Semax extends a fragment of ACTH, a hormone involved in the stress response. Selank extends tuftsin, an immune-related fragment released from an antibody. Both are synthetic chains of seven amino acids. Similar length and a shared extension do not establish the same biological effects.

DSIP is a nine-amino-acid peptide first characterized through rabbit sleep experiments. It has been reported in biological samples, yet the way it is produced and the identity of a specific receptor remain unresolved. “Natural” and “synthetic” describe different facts about origin; neither word supplies a safety conclusion.

For Semax, rat BDNF research concerns a protein involved in nerve-cell survival and connections. For Selank, rat gene research concerns GABA signaling, which generally dampens nerve-cell firing. These experiments measure different things in animals. Neither establishes how a healthy reader performs at work.

DSIP’s critical review highlights a more basic uncertainty: its proposed sleep role is not well established and its specific receptor remains unidentified. That makes a confident account of exactly what it does in people especially difficult. A longer history does not automatically provide a firmer mechanism.

There is no large human trial establishing which of these compounds is best for a healthy person’s focus, memory or calm. Small Russian Semax studies concern neurological illness or brain activity. Selank’s 62-patient anxiety comparison lacked a placebo group and does not state randomization or blinding in its abstract.

A double-blind DSIP study in people with chronic insomnia reported modest effects of limited clinical importance. Its participants and research questions differed from those in the anxiety studies.

None of the three has the large, long-term human safety record needed for confident estimates across many health situations. Inadequate adverse-effect reporting can hide uncertainty. Other medicines and existing conditions can matter even when a proposed mechanism sounds gentle.

Anecdotal, not clinical evidence

People online may favor one name for clarity, another for calm and another for sleep. Reports also include discomfort and no apparent change. Such preferences cannot separate expectation, product differences or concurrent substances, and they do not rank clinical effectiveness.

Each request through Promise Peptides reaches a licensed U.S. provider for an individual decision. The assessment can find that a person is not eligible. The route serves U.S. patients, and availability varies with state and treatment. When prescribed, the blend or DSIP is prepared by a licensed U.S. compounding pharmacy.

The medicines described here are compounded and are not FDA-approved. A live product page establishes an access route, rather than a comparative clinical advantage. Our process guide explains the next step and why a provider may decide against prescribing.